ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0342

RAIL Distinguishes Responder and Non-Responder in Pediatric Lupus Nephritis
Abstract Number: 0343

Overview of the Childhood Systemic Lupus Erythematosus (cSLE) Cohort in the CARRA Registry
Abstract Number: 0344

Anti-gAChR Antibody as a Novel Biomarker for Lupus Enteritis in Systemic Lupus Erythematosus
Abstract Number: 0345

Anti-MPP-1 Autoantibodies in Systemic Lupus Erythematosus: A Potential Biomarker for Neuropsychiatric Manifestations
Abstract Number: 0346

The CB-CAPillaryTM Test Kit: A Tool for Point-of-Care Assays to Measure Cell-Bound Complement Activation Products
Abstract Number: 0347

Longitudinal ANA Titers in SLE and ANA+ Controls
Abstract Number: 0348

The New EULAR/ ACR 2019 SLE Classification Criteria: A Predictor of Long-term Outcomes
Abstract Number: 0349

Performance of the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Predominantly African American Cohort
Abstract Number: 0350

EPI-SIGN: Epigenetic SLE Indicators of Glomerular Nephritis
Abstract Number: 0351

Gene Signature Fingerprints Divide SLE Patients in Subgroups with Similar Biological Disease Profiles: A Multicenter Longitudinal Study
Abstract Number: 0352

Native American and African American Rheumatic Disease Patients Exhibit Accelerated Biological Aging Compared to European Americans
Abstract Number: 0353

Soluble Urine ALCAM Reflects Renal Disease Activity in Lupus Nephritis
Abstract Number: 0354

A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus
Abstract Number: 0355

Utilization of a Clinical Data Research Network to Assess Systemic Lupus International Collaborating Clinics Classification Criteria Attributes in Patients with Systemic Lupus Erythematosus
Abstract Number: 0356

The Role of Neutrophils in the Clinical Severity of Lupus Nephritis Patients with Concurrent Skin Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].